Cantargia
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Cantargia is a clinical-stage biotechnology company, founded in 2010, that develops antibody-based pharmaceuticals for life-threatening diseases. The company specializes in therapies targeting the interleukin-1 receptor accessory protein (IL1RAP), a molecule involved in cancer and inflammatory/autoimmune conditions. Its lead asset, nadunolimab (CAN04), is in clinical development for the treatment of various cancers. In 2025, Cantargia's CAN10 immunology program was acquired by Otsuka Pharmaceutical, highlighting the potential of its therapeutic platform.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Cantargia and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-11 07:30 |
M&A Activity
Cantargia closes the acquisition of CAN10 by Otsuka
|
English | 104.2 KB | |
| 2025-09-11 07:30 |
M&A Activity
Cantargia slutför Otsukas förvärv av CAN10
|
Swedish | 103.9 KB | |
| 2025-08-21 07:00 |
Interim Report
|
Swedish | 3.5 MB | |
| 2025-08-21 07:00 |
Interim Report
|
English | 3.5 MB | |
| 2025-08-18 18:25 |
Board/Management Information
Cantargia utnämner Dr Hilde Steineger till verkställande direktör
|
Swedish | 107.1 KB | |
| 2025-08-18 18:25 |
Board/Management Information
Cantargia appoints Dr Hilde Steineger as Chief Executive Officer
|
English | 107.8 KB | |
| 2025-07-17 21:30 |
Regulatory News Service
Cantargia announces preliminary topline efficacy results from the phase 2 TRIFO…
|
English | 117.3 KB | |
| 2025-07-17 21:30 |
Earnings Release
Cantargia meddelar preliminära topline-effektresultat från fas 2-studien TRIFOU…
|
Swedish | 118.2 KB | |
| 2025-07-15 08:45 |
M&A Activity
Cantargia tillkännager försäljningen av IL1RAP immunologiprogrammet CAN10 till …
|
Swedish | 111.6 KB | |
| 2025-07-15 08:45 |
M&A Activity
Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by O…
|
English | 111.5 KB | |
| 2025-07-08 10:17 |
Major Shareholding Notification
|
Swedish | 9.5 KB | |
| 2025-06-17 19:45 |
Capital/Financing Update
Cantargia tecknar avtal om lånefacilitet om 50 miljoner kronor, som förlänger b…
|
Swedish | 107.1 KB | |
| 2025-06-17 19:45 |
Capital/Financing Update
Cantargia signs SEK 50 million financing facility agreement, extending cash run…
|
English | 107.4 KB | |
| 2025-05-15 16:30 |
Post-Annual General Meeting Information
Bulletin from the Annual General Meeting in Cantargia AB
|
English | 93.9 KB | |
| 2025-05-15 16:30 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Cantargia AB
|
Swedish | 94.8 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-01-19 | Ignacio Garcia Ribas | Other | Buy | 1,471 | 9,826.28 EUR |
| 2021-01-19 | Ignacio Garcia Ribas | Other | Buy | 1,471 | 9,414.40 EUR |
| 2021-01-18 | Bengt Jöndell | Other | Buy | 1,000 | 62,200.00 SEK |
| 2021-01-18 | Göran Forsberg | Other | Buy | 2,000 | 123,000.00 SEK |
